A large proportion of adult patients with acute myeloid leukemia (AML) relapse after
treatment, and some of them are resistant to primary induction chemotherapy. Sixty-one …

Sixty-two patients with high-risk acute leukemia were treated with the FLAD regimen [3 days
of treatment with fludarabine 30 mg/m 2, cytarabine (AraC) 2 g/m 2, and liposomal …

Therapeutic options for patients with relapsed or refractory acute leukemia are still
undefined and often unsatisfactory. We report the outcome of 79 patients with relapsed …

We did a retrospective analysis on the safety and efficacy of sequential infusion fludarabine
and cytosine arabinoside (ara-C) in treating refractory, recurrent or poor prognosis acute …

Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete
remission was observed in 54% of cases but the median duration of remission was short (4 …

Abstract In 1992–1993, synergistic interaction of ribonucleotide reductase inhibitors
(fludarabine, cladribine) and cytarabine (Ara-C) increasing Ara-CTP concentration in …

Patients with refractory acute leukemias after intensive induction and salvage attempts have
a particularly poor prognosis and therapeutic options are limited. In the current study, the …

We assessed continuous infusion (CI) of fludarabine and cytarabine (FLAG) plus idarubicin
for patients under 60‐years old with resistant acute myeloid leukemia (AML). Induction …

The current phase-II trial was initiated to assess the efficacy and toxicity of the Ida-FLAG
regimen in patients with poor-risk acute myeloid leukemia (AML). Three subgroups of …

BACKGROUND AND OBJECTIVES: A phase II study was conducted to investigate the
effects of a therapeutic program based on the combination of fludarabine and cytarabine …